We are honored to share the third patient story in our "All the Difference" series, where extraordinary individuals share their experiences living with...
This blog was written by Karen Murphy, Patient Assistance Liaison at Orsini Specialty Pharmacy It’s an unfortunate truth that although incredible...
We are honored to share the second eBook in our "All the Difference" series, where extraordinary individuals share their experiences living with rare...
Prior authorization is used by health insurance companies to determine whether they will cover a prescribed procedure, service, or medication for a...
Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that it has been...
For a pharmaceutical manufacturer, it's essential to find a strategic partner to optimize individual therapies to provide the highest quality clinical...
Rare diseases impact individuals and families worldwide. We are honored to participate in Rare Disease Day to help raise awareness among the general...
Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced today that it has been selected as the exclusive specialty pharmacy...
Spinal muscular atrophy (SMA) is a genetic disease that affects the central nervous system, peripheral nervous system, and voluntary muscle movement,...
We are excited to share the first eBook in our "All the Difference" series, where extraordinary individuals share their experiences living with rare...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)